Moreover, modification of the glucagon-like peptide 1 (GLP-1)-based drug Liraglutide®, which features a C16 lipid chain responsible, in part, for its longer duration of action, by adding a PEG-like spacer gave Semaglutide®, which can be administered once weekly and is used in the treatment of type 2 diabetes and obesity [28,29]. The gene discussed is GCG; the disease is obesity disorder.